Compare ACIU & RWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACIU | RWAY |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 277.7M |
| IPO Year | 2015 | N/A |
| Metric | ACIU | RWAY |
|---|---|---|
| Price | $2.81 | $6.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $10.00 | $9.50 |
| AVG Volume (30 Days) | 262.2K | ★ 615.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 21.54% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $706.75 | $1.26 |
| Revenue Next Year | $321.13 | $1.25 |
| P/E Ratio | ★ N/A | $5.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $6.36 |
| 52 Week High | $4.00 | $11.41 |
| Indicator | ACIU | RWAY |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 48.54 |
| Support Level | $2.80 | $6.48 |
| Resistance Level | $3.13 | $6.97 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 31.00 | 51.72 |
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States. The company's investment objective is to maximize its total return to its stockholders through current income on its loan portfolio, and secondarily through capital gain on its warrants and other equity positions.